NorthWest Biotherapeutics Inc (NWBO)

[Maverick0408]

It does matter, Gary. We continue to get diluted at these prices. It’s likely we go under under 50 or 40 cents before we get any regulatory news depending on the timing. Furthermore, it’s likely we could be over 1.3B outstanding shares with almost half of preferred C shares that were authorized in Dec 2022 gone, again depending on timing. At that point upside will be muted. Perhaps it doubles from 40 to 80 cents on UK MHRA approval news in 2024 and then finally settles again at 60 or 70 cents!

This is what I see happening without big pharma partnership. The street will not see this management any differently from when they released JAMA, TLD, and MIA news. They will poke holes at managements ability to scale themselves,
investment needed to scale, reimbursement challenges in UK for subset of population, etc. Needless to say, the saga will continue! Only way to change that perception and credibility in the marketplace is to get a formidable big pharma partner on board who sees the value in our platform and broadcasts it to the world by paying a rich premium on the approved DCVAX-L for GBM indication (commercial partnership around GBM revenue sharing). This way, they do the heavy lifting on (indirect) branding building and rapid revenue generation while NWBO focuses on running additional trials for other indications with the large upfront payment they get from big pharma.